Vendor Intelligence Report: Huayi Biotechnology

Executive summary

Huayi Biotechnology is a product-specific call, not a blanket reject. Across 42 Finnrick lab tests, the current Huayi record reports 38 pass / 3 fail, an overall pass rate of 90%. The usable signal is uneven: GHK-Cu and Tirzepatide are the defensible choices, Retatrutide needs lot-matched confirmation, and BPC-157 is the weak spot. Stricter scoring views also separate passing purity from fill, supply, and consistency risk.

The business record is much less clean than the best lab results. The primary Shoplazza storefront was closed in repeated captures, while an active secondary domain presented the catalog through Shop910 assets. Registry work did not verify a Chinese Huayi operating entity from accessible sources; instead, the file ties the address footprint and displayed qualification certificates to Tongkang entities, with company-name areas obscured and scopes outside peptide manufacturing.

The infrastructure finding is not a lab-failure finding; it is a buyer-recourse finding. Shop910 materials reviewed in the report advertise AB Jump Rotation, a Cloak system, and special-goods payment support, creating a transaction environment where buyers, crawlers, and processors may not see the same flow. The report also examines SV-branded vials, COAs with weak batch fields, catalog breadth beyond ordinary research peptides, and Huayi-targeted review redirects leading to a generic peptide sales page.

Practical read: if buying Huayi, treat GHK-Cu and Tirzepatide as the products best supported by current Finnrick data, and require fresh lot-matched testing for Retatrutide. Do not let those results carry BPC-157 or Huayi’s manufacturer claims; unresolved operator, certificate, and payment-rail issues remain independent risks.

Inside the full report:

• Appendix A test-level lab data, product-rating trajectories, and methodology-divergence charts
• Operating timeline covering the closed Shoplazza storefront, secondary domain, archive gap, and domain registration
• Shop910 infrastructure review covering AB Jump Rotation, cloaking, CDN paths, and special-payment context
• Tongkang certificate, address, and facility-image attribution analysis
• SV vial, Janoshik COA, and batch-traceability review
• Search-reputation scan covering Huayi-targeted review redirects and unresolved social/contact channels

Risk assessment

• Misrepresented qualification and facility-claim risk — high: Displayed certificates trace to Tongkang cosmetics / medical-device entities; factory images use a non-Huayi Shop910 CDN path rather than a verified Huayi facility record.
• Gray-market cloaking and payment-infrastructure risk — high: huayibiotechnology.com uses Shop910 infrastructure whose own materials advertise AB Jump Rotation, Cloak system, and special-goods payment features.
• COA, batch-traceability, and manufacturer-visibility risk — high: SV-branded vials, unknown SV origin, and vendor-displayed reports with Unknown batch fields prevent reliable lot-level verification.
• Catalog legal and seizure risk — high: Catalog review found 1-Benzyl-4-piperidone, anabolic steroids, SARMs, and GW-501516, expanding legal/import exposure beyond ordinary research peptides.
• Corporate identity and operator-opacity risk — medium: No verified Chinese operating registration was found from accessible sources; three listed managers share one QQ email and storefront history is thin.
• Product-specific quality risk: BPC-157 — medium: BPC-157 is 54.72% over 4 tests with 3 pass / 1 fail; GHK-Cu and Tirzepatide are stronger Huayi choices.
• Search-manipulation and brand-confusion risk — medium: Huayi-targeted review domains redirected to a generic peptide page, while similar Huayi names and typo-like social handles exist without a strong official-channel list.